Advancing GPCR19 Positive Allosteric Modulation: Phase I Data From NuCerin, a First-in-Class Therapy for Alzheimer’s Disease

• Unravelling the mechanism of action of GPCR19 agonism
• Demonstrating simultaneous targeting of Aβ and neuroinflammation
• Reviewing results and key takeaways from the Phase I trial of NuCerin in South Korea

Speakers:

Shawn Seong

Chief Executive Officer

Shaperon